Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentaglobin for Febrile Neutropenia in CRE/PA Colonized Patients
NCT03494959Phase 2Active, not recruiting
- Sponsor
- GITMO
- Start
- Dec 2019
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pentaglobin in febrile neutropenia (FN), sepsis and septic shock, sponsored by GITMO. Primary endpoints: Sepsis-related mortality at 30 days and Overall Survival at 4 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
Pentaglobin
03
Conditions
febrile neutropenia (FN)sepsisseptic shock
Beyond the preview
Go deeper on NCT03494959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494959.